Open Access Articles- Top Results for Telbivudine


File:Telbivudine structure.svg
Systematic (IUPAC) name
Clinical data
Trade names Tyzeka
AHFS/ monograph
MedlinePlus a607045
Licence data EMA:Link, US FDA:link
  • US: B (No risk in non-human studies)
Pharmacokinetic data
Protein binding Low (3.3% in vitro)
Metabolism Nil
Half-life 40 to 49 hours (terminal phase)
Excretion Renal
3424-98-4 7pxY
PubChem CID 159269
DrugBank DB01265 7pxY
ChemSpider 140081 7pxY
ChEMBL CHEMBL374731 7pxN
Synonyms 1-(2-deoxy-β-L-ribofuranosyl)-5-methyluracil
β-L-thymidine (LdT)
Chemical data
Formula C10H14N2O5
242.23 g/mol
 14pxN (what is this?)  (verify)

Telbivudine is an antiviral drug used in the treatment of hepatitis B infection. It is marketed by Swiss pharmaceutical company Novartis under the trade names Sebivo (Europe) and Tyzeka (United States). Clinical trials have shown it to be significantly more effective than lamivudine or adefovir, and less likely to cause resistance.[1][2][3]

Telbivudine is a synthetic thymidine nucleoside analogue; it is the L-isomer of thymidine. It is taken orally in a dose of 600 mg once daily with or without food.


  1. ^ Lai CL, Leung N, Teo EK et al. (2005). "A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B". Gastroenterology 129 (2): 528–36. PMID 16083710. doi:10.1016/j.gastro.2005.05.053. 
  2. ^ Lai CL, Gane E, Liaw YF et al. (2007). "Telbivudine versus lamivudine in patients with chronic hepatitis B". N Engl J Med 357 (25): 2576–88. PMID 18094378. doi:10.1056/NEJMoa066422. 
  3. ^ Chan HL, Heathcote EJ, Marcellin P et al. (4 December 2007). "Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial". Ann Intern Med 147 (11): 745–54. PMID 17909201. doi:10.7326/0003-4819-147-11-200712040-00183. 

External links

Lua error in package.lua at line 80: module 'Module:Buffer' not found.